ArticleInternational journal of general medicine2026
Evaluation of the Berden Classification and ANCA Kidney Risk Score in Biopsy-Proven ANCA-Associated Glomerulonephritis: Associations with Clinical Characteristics and Outcomes.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to evaluate the associations of the Berden histopathological classification and the ANCA Renal Risk Score (ARRS) with renal outcomes and overall survival in patients with biopsy-proven ANCA-associated glomerulonephritis. Methods: This retrospective study included 54 adult patients with ANCA-associated vasculitis and biopsy-proven renal involvement between June 2016 and June 2023. Renal biopsies were categorized according to the Berden classification, and patients were stratified into low-, medium-, and high-risk groups according to the ARRS. Clinical, laboratory, treatment, renal outcome, and survival data were compared across the classification groups. Overall survival was assessed using Kaplan-Meier analysis and Cox proportional hazards regression. Results: Among 54 patients, 33.3% were classified as crescentic, 31.5% as focal, 20.4% as mixed, and 14.8% as sclerotic according to the Berden classification; 14.8%, 46.3%, and 38.9% were categorized as low-, medium-, and high-risk according to the ARRS, respectively. Baseline serum creatinine differed significantly across both Berden classes (p=0.025) and ARRS categories (p=0.035). Progression to end-stage renal disease (ESRD) also differed significantly across Berden classes (p=0.046) and ARRS categories (p=0.012), with the highest frequencies observed in the sclerotic class (50.0%) and high-risk ARRS group (33.3%). All eight ESRD events occurred in patients with baseline eGFR <15 mL/min/1.73 m Conclusion: The Berden classification and ARRS were associated with renal disease severity and progression to ESRD but not with overall survival in this cohort. Severe renal dysfunction at presentation, particularly an eGFR <15 mL/min/1.73 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.